Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Long-Term Debt Repayments (2023 - 2025)

Perspective Therapeutics' Long-Term Debt Repayments history spans 5 years, with the latest figure at $13000.0 for Q3 2025.

  • For Q3 2025, Long-Term Debt Repayments fell 18.75% year-over-year to $13000.0; the TTM value through Sep 2025 reached $51000.0, up 6.25%, while the annual FY2024 figure was $48000.0, 29.41% down from the prior year.
  • Long-Term Debt Repayments for Q3 2025 was $13000.0 at Perspective Therapeutics, roughly flat from $13000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $21000.0 in Q3 2023 and bottomed at $8000.0 in Q2 2024.
  • The 3-year median for Long-Term Debt Repayments is $13000.0 (2025), against an average of $14090.9.
  • The largest annual shift saw Long-Term Debt Repayments crashed 60.0% in 2024 before it surged 62.5% in 2025.
  • A 3-year view of Long-Term Debt Repayments shows it stood at $12000.0 in 2023, then changed by 0.0% to $12000.0 in 2024, then increased by 8.33% to $13000.0 in 2025.
  • Per Business Quant, the three most recent readings for CATX's Long-Term Debt Repayments are $13000.0 (Q3 2025), $13000.0 (Q2 2025), and $13000.0 (Q1 2025).